FUDAN ZHANGJIANG (01349)Qin Lei resigns as Deputy General Manager

19:48 13/05/2026

Fudan Zhangjiang (01349) announced that the board of directors recently received written materials from the company's vice general manager, Mr. Qin Lei, and a resignation application submitted by Mr. Qin Lei during the company's office procedures. Mr. Qin Lei has applied to resign from his position as vice general manager and will not hold any other position in the company after his resignation. Mr. Qin Lei is currently handling the handover procedures with relevant employees, and his official departure date is May 27, 2026.

FUDAN ZHANGJIANG (01349) Announcement: The Board of Directors recently received written materials from Mr. Qin Lei, the company's Vice General Manager, regarding his resignation application submitted during the company's office procedures. Mr. Qin Lei has applied to resign from his position as Vice General Manager, and after resigning, he will no longer hold any other position within the company. Mr. Qin Lei is currently in the process of handing over his work to relevant employees, and his official departure date is May 27, 2026.

XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.

Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.

XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.

Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.